Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KFRX-03
- Development stage
- Preclinical
- Lead developer
- KeifeRx
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
KFRX-03 is a small molecule, oral tyrosine kinase inhibitor developed by KeifeRx for the treatment of neurodegenerative and immune diseases. It selectively inhibits ABL1 (ABL proto-oncogene 1), FYN (tyrosine-protein kinase FYN), and c-Kit (stem cell growth factor receptor) kinases. The drug is designed to cross the blood-brain barrier, restore autophagy, and remove toxic protein buildup in the brain, which may be beneficial in conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, mastocytosis, Lyme disease, Parkinson's disease with dementia (PDD), frontotemporal dementia, mast cell activation syndromes (MCAS), and urticaria. KFRX-03 aims to provide new therapeutic options with high central nervous system exposure while minimizing off-target side effects[1][3][5].
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)FYN (Proto-oncogene tyrosine-protein kinase Fyn)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on KFRX-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KFRX-03.